Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Designing CAR T cells for glioblastoma.

Literature DB >> 26587317

Designing CAR T cells for glioblastoma.

Abstract

Chimeric antigen receptor (CAR)-modified T cells directed against CD19 can mediate long-term durable remissions in B cell malignancies, but bringing a new target antigen to the clinic requires extensive modeling to avoid on-target and off-target toxicity. We recently described a systematic approach to test a new CAR directed against EGFR variant III.

Entities: Disease Gene

Keywords: CAR T cells, glioblastoma, EGFRvIII, adoptive cell therapy

Year: 2015 PMID： 26587317 PMCID： PMC4635938 DOI： 10.1080/2162402X.2015.1048956

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

1. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors: David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245

2. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors: Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal: Mol Ther Date: 2010-02-23 Impact factor: 11.454

3. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors: Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544

4. Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245

5. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.

Authors: Laura A Johnson; John Scholler; Takayuki Ohkuri; Akemi Kosaka; Prachi R Patel; Shannon E McGettigan; Arben K Nace; Tzvete Dentchev; Pramod Thekkat; Andreas Loew; Alina C Boesteanu; Alexandria P Cogdill; Taylor Chen; Joseph A Fraietta; Christopher C Kloss; Avery D Posey; Boris Engels; Reshma Singh; Tucker Ezell; Neeraja Idamakanti; Melissa H Ramones; Na Li; Li Zhou; Gabriela Plesa; John T Seykora; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal: Sci Transl Med Date: 2015-02-18 Impact factor: 17.956

6. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors: Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal: N Engl J Med Date: 2013-03-25 Impact factor: 91.245

7. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors: Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal: J Immunother Date: 2013-02 Impact factor: 4.456

8. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Authors: Gerald P Linette; Edward A Stadtmauer; Marcela V Maus; Aaron P Rapoport; Bruce L Levine; Lyndsey Emery; Leslie Litzky; Adam Bagg; Beatriz M Carreno; Patrick J Cimino; Gwendolyn K Binder-Scholl; Dominic P Smethurst; Andrew B Gerry; Nick J Pumphrey; Alan D Bennett; Joanna E Brewer; Joseph Dukes; Jane Harper; Helen K Tayton-Martin; Bent K Jakobsen; Namir J Hassan; Michael Kalos; Carl H June
Journal: Blood Date: 2013-06-14 Impact factor: 22.113

9. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors: Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal: Blood Date: 2009-05-18 Impact factor: 22.113

10. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Authors: Brian J Cameron; Andrew B Gerry; Joseph Dukes; Jane V Harper; Vivekanandan Kannan; Frayne C Bianchi; Francis Grand; Joanna E Brewer; Minnal Gupta; Gabriela Plesa; Giovanna Bossi; Annelise Vuidepot; Alex S Powlesland; Alison Legg; Katherine J Adams; Alan D Bennett; Nicholas J Pumphrey; Daniel D Williams; Gwendolyn Binder-Scholl; Irina Kulikovskaya; Bruce L Levine; James L Riley; Angel Varela-Rohena; Edward A Stadtmauer; Aaron P Rapoport; Gerald P Linette; Carl H June; Namir J Hassan; Michael Kalos; Bent K Jakobsen
Journal: Sci Transl Med Date: 2013-08-07 Impact factor: 17.956

10 in total

12 in total

Designing CAR T cells for glioblastoma.

1. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

2. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

3. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

4. Chimeric antigen receptor T cells for sustained remissions in leukemia.

5. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.

6. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

7. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

8. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

9. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

10. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Review 1. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

Review 2. Single vs. combination immunotherapeutic strategies for glioma.

Review 3. Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy.

4. CAR-T Cell Therapy: From the Bench to the Bedside.

5. CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.

Review 6. New Chimeric Antigen Receptor Design for Solid Tumors.

Review 7. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

Review 8. Chimeric antigen receptor T cells: a novel therapy for solid tumors.

Review 9. Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment.

10. DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers.